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Gamma-Linolenic and Pinolenic Acids Exert
Anti-Inflammatory Effects in Cultured Human Endothelial
Cells Through Their Elongation Products
Ella J. Baker,* Carina A. Valenzuela, Wies T.M. van Dooremalen,
Leyre Martínez-Fernández, Parveen Yaqoob, Elizabeth A. Miles, and Philip C. Calder
Scope: Omega-3 fatty acids (FAs) from oily fish reduce cardiovascular
disease. This may be partly due to modulation of endothelial cell (EC)
inflammation. Fish stocks are declining and there is a need for sustainable
alternative FAs. Gamma-linolenic acid (GLA) and pinolenic acid (PLA) are
plant-derived FAs, which can fulfil this role.
Methods and results: EA.hy926 cells are exposed GLA and PLA prior to
stimulation with tumor necrosis factor (TNF)-𝜶. GLA and PLA are
incorporated into ECs, resulting in increases in long-chain derivatives
produced by elongase 5, dihomo-gamma-linolenic acid (DGLA), and
eicosatrienoic acid (ETA). Both GLA and PLA (50 µm) decrease production of
soluble intercellular adhesion molecule-1 (sICAM-1), monocyte
chemoattractant protein 1 (MCP-1), and regulated on activation, normal T cell
expressed and secreted (RANTES). However, decreases in these mediators are
not seen after pre-treatment with GLA or PLA in elongase 5 silenced EA.hy926
cells. DGLA and ETA (10 µm) decrease EC production of sICAM-1, MCP-1,
RANTES, and IL-6. All FAs reduce adhesion of THP-1 monocytes to EA.hy926
cells. Both PLA (50 µm) and ETA (10 µm) decrease NF𝜿Bp65 phosphorylation.
Conclusion: These effects suggest potential for GLA, PLA and their long-chain
derivatives, DGLA and ETA, as sustainable anti-inflammatory alternatives to
fish-derived FAs.
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1. Introduction
Atherosclerosis is considered to be an
inflammatory disease, and endothelial
cell (EC) dysfunction plays a pivotal
role in its pathogenesis.[1–3] The dysfunc-
tional endothelium, which can arise from
unresolved inflammation, promotes an
influx of leukocytes, especially mono-
cytes, into the intimal layer of the
artery wall.[4] These monocytes differen-
tiate into macrophages which become
lipid laden so promoting atherosclerotic
plaque formation.[5,6] Very long chain
omega-3 (n-3) polyunsaturated fatty acids
(PUFAs), particularly eicosapentaenoic
acid (EPA) and docosahexaenoic acid
(DHA), have anti-inflammatory and anti-
atherogenic actions and their consump-
tion is associated with lowering of risk for
cardiovascular disease (CVD).[7–11] In or-
der to understand their actions and the
mechanisms involved, studies have ex-
amined the effects of EPA and DHA on
endothelial and leukocyte functions.[12,13]
EPA and DHA are found predominantly
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Figure 1. The pathway of metabolic conversion of gamma-linolenic acid and the likely pathway of conversion of pinolenic acid to longer-chain polyun-
saturated fatty acids. Genes encoding the various enzymes are shown in brackets.
in fatty fish and many authorities recommend regular consump-
tion of fatty fish to achieve health benefits.[14] However, cur-
rent fish stocks are declining and so more sustainable sources
of health benefiting bioactive fatty acids need to be explored.[15]
Gamma-linolenic acid (GLA) and pinolenic acid (PLA) are plant-
derived fatty acids, which may provide alternative sustainable
sources of bioactive PUFAs that target inflammation.
GLA is found in some leafy green vegetables, vegetable oils,
and nuts, including evening primrose (Oenothera beinnis) oil
and borage (Borage officinalis) oil.[16] PLA, a poly-methylene-
interrupted PUFA, is found exclusively in pine nut oil (present
at about 15% of FAs).[17] There are older studies exploring the
anti-inflammatory effects of GLA,[18,19] but its effect on endothe-
lial inflammation is not known. There has been little exploration
of the functionality and potential benefits of PLA.
Studies examining the effects of GLA identified that its actions
seem to be due to its elongated derivative dihomo-gamma-
linolenic acid (DGLA). This conversion, catalyzed by elongase 5,
is shown in Figure 1. Elongase 5 is encoded by the ELOVL5 gene.
DGLA can be further desaturated to arachidonic acid (Figure 1).
When cells, laboratory animals, or humans are provided with
GLA, cells, including those involved in inflammation, such
as neutrophils and mononuclear cells, become enriched in
DGLA.[20] DGLA is a precursor of eicosanoids produced via the
cyclooxygenase (COX) and lipoxygenase (LOX) pathways. These
include the 1-series prostaglandins, such as prostaglandin E1
(PGE1), which has been found to possess anti-inflammatory
properties, including inhibition of smooth muscle cell prolifera-
tion associated with atherosclerotic plaque development.[21] The
pathway of conversion of PLA to derivatives analogous to DGLA
has not been fully described; however Szu-jung Chen et al. sug-
gested that PLA can be converted to eicosatrienoic acid (ETA) in
microglial BV-2 cells and described incubation with PLA to lead
to reduced production of several pro-inflammatory mediators,
including interleukin (IL)-6, prostaglandin E2 (PGE2), and tumor
necrosis factor alpha (TNF-𝛼) in response to stimulation with
lipopolysaccharide (LPS).[22] Conversion of PLA to ETA is likely
to be catalyzed by elongase 5 (Figure 1).
Both EPA and DHA have been shown to have anti-
inflammatory effects in ECs, including lowering of surface ex-
pression of adhesion molecules, reduced monocyte adhesion,
and decreased inflammatory marker expression, at the levels of
both protein and messenger RNA.[23–27] These effects are likely
to be linked to decreased atherosclerosis. Previously we showed
EPA and DHA to have multiple anti-inflammatory effects in the
EA.hy926 EC line.[28] In the current study, effects of GLA and
PLA, and their elongation products, DGLA and ETA, on the in-
flammatory responses of EA.hy926 cells were examined.
2. Results
2.1. Results of MTT Assay: Effects of GLA and PLA on EA.hy926
Cell Viability
Cell mitochondrial activity was measured using the MTT assay
and viability was calculated as a % of control (cells in DMEMplus
supplements). Exposure to TNF-𝛼 at 1 ngmL−1 for 24 h had no ef-
fect on cell viability. Figure 2A,B shows viability of cells cultured
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Figure 2. A,B) Viability of EA.hy926 cells after incubation for 48 h with DMEM containing 0.1% of ethanol (control; CTL) or fatty acids (GLA [A] and PLA
[B]) at 10, 25, 50, or 100 µm followed by incubation with or without TNF-𝛼 (1 ng mL−1) for 24 h (n = 3, two-way ANOVA with Tukey’s post hoc test:
no significant differences). C,D) Incorporation of fatty acids (GLA and PLA) and appearance of elongation products after incubation of EA.hy926 cells
for 48 h with DMEM containing 0.1% of ethanol (control) or fatty acids (GLA [C] and PLA [D]) at 10 or 50 µm (n = 3, one-way ANOVA with Dunnett’s
post-hoc test: Fatty acid vs control, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001). E) MS total ion chromatogram depicting 1) the ion
fragments of the FA produced in EA.hy926 cells after 48 h treatment with PLA at 50 µm and 2) the total ion chromatogram of eicosatrienoic acid (ETA)
taken from the Lipidhome database.[29]
with GLA or PLA at 10, 25, and 50 µm. Treatment with FAs for
48 h at any concentration followed by 24 h 1 ng mL−1 TNF-𝛼 ex-
posure had no effect on EA.hy926 cell viability. Based on these
results, GLA and PLA at all concentrations were found to be suit-
able for further experiments.
2.2. Identification and Incorporation of FAs in EA.hy926 Cells
FA incorporation into EA.hy926 cells was determined by gas
chromatography. Both GLA and PLA were incorporated into
EA.hy926 cells in a concentration-dependent manner, with the
appearance of longer chain derivatives (Figure 2C,D). PLA treat-
ment led to the increase of an FA that was not identifiable
through standard gas chromatography. Gas chromatography–
mass spectrometry was used to identify this FA. Figure 2E-1,2 de-
picts the MS total ion chromatogram of the unknown FA present
in EA.hy926 cells after exposure to PLA. The unknown fatty acid
was identified to be ETA when compared to standards on the
Lipidhome database[29] (Figure 2E-2).
GLA treatment at 10 µm did not enrich cells with GLA, but sig-
nificantly increased DGLA content (p < 0.05) (Figure 2C). GLA
treatment at 50 µm led to a significant increase in both GLA
(p < 0.01) and DGLA (p < 0.001) (Figure 2C). Pre-treatment with
GLA did not significantly change levels of arachidonic acid in
EA.hy926 cells (Figure 2C). Incubation of EA.hy926 cells with
PLA at 10 µm led to a significant increase in ETA (p< 0.05), while
treatment with PLA at 50 µm led to an increase in both PLA (p <
0.001) and ETA (p < 0.0001) (Figure 2D). Levels of DGLA and
ETA exceeded those of GLA and PLA.
2.3. Effects of GLA and PLA on Inflammatory Mediators
Produced by EA.hy926 Cells
TNF-𝛼 stimulation (24 h at 1 ng mL−1) led to significantly in-
creased production of all inflammatorymediators examined (data
not shown). FA exposure had differential effects depending on
the individual FA and on FA concentration (Figure 3A–E).
At a concentration of 10 µm, GLA did not significantly alter the
production of any of the five mediators studied. However, GLA
treatment at 25 and 50 µm led to significant reduction in secretion
of sICAM-1 (p < 0.01, p < 0.01, respectively). Exposure of GLA at
50 µm also led to significant decreases in the production of both
MCP-1 (p < 0.001) and RANTES (p < 0.01) by EA.hy926 cells.
PLA treatment at 10 µm decreased the production of
sICAM-1 (p < 0.05); this effect was also seen after treatment with
25 and 50 µm PLA (p < 0.01, p < 0.001, respectively). Treatment
of EA.hy926 cells with PLA at 50 µm also reduced the production
of both MCP-1 (p < 0.001) and RANTES (p < 0.01).
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Figure 3. Concentrations (pg mL−1) of A) ICAM-1, B) MCP-1, C) IL-6, D) IL-8, and E) RANTES in the medium of EA.hy926 cells incubated for 48 h with
DMEM containing 0.1% of ethanol (CTL) or fatty acids (GLA or PLA) at 10, 25, or 50 µm, followed by incubation with TNF-𝛼 (1 ng mL−1) for 24 h (n =
3, two-way ANOVA with Tukey’s post hoc test: Fatty acid vs control, *p < 0.05 and **p < 0.01). F) Protein expression of pNF𝜅Bp65 and NF𝜅Bp65 in
EA.hy926 cells incubated for 48 h with DMEM containing 0.1% of ethanol (control, CTL) or fatty acids (GLA or PLA) at 50 µm, followed by incubation
with TNF-𝛼 (1 ng mL−1) for 1 h (data are normalized to loading control (GAPDH)) (n = 3, one-way ANOVA with Tukey’s post hoc test: Fatty acid vs
control, **p < 0.01).
2.4. Effects of GLA and PLA on NF𝜿Bp65 Protein Expression in
EA.hy926 Cells
Pre-treatment with GLA (50 µm) had a tendency to decrease
the ratio of phosphorylated nuclear factor kappa-light-chain-
enhancer of activated B cells (pNF𝜅B)p65/NF𝜅Bp65, al-
though this was not significant (Figure 3F). In contrast,
PLA (50 µm) treatment significantly decreased the ratio of
pNF𝜅Bp65/NF𝜅Bp65 (p < 0.01) (Figure 3F).
2.5. Effects of GLA and PLA on Expression of ICAM-1 on
EA.hy926 Cells
TNF-𝛼 was shown to up-regulate ICAM-1 cell-surface expression
on EA.hy926 cells.[28] GLA and PLA treatment at either concen-
tration (25 or 50 µm) did not affect either the level of ICAM-1 ex-
pression (MFI) (Figure 4A) or the % of cells expressing ICAM-1
(Figure 4B) compared to stimulated control cells.
2.6. Effects of GLA and PLA on THP-1 Adhesion to EA.hy926 Cells
Adhesion of calcein-labeled THP-1 cells to EA.hy926 cells was
shown to significantly increase with TNF-𝛼 stimulation of the
ECs (data not shown). Neither GLA nor PLA had any effect
on THP-1 adhesion at a concentration of 25 µm; however both
GLA and PLA reduced adhesion of THP-1 cells to EA.hy926
cells when used at a concentration of 50 µm (Figure 4C).
Treatment with GLA and PLA at 50 µm reduced adhesion of
THP-1 cells by ≈28% and ≈23%, respectively (p < 0.001, p <
0.01) compared to stimulated control cells (Figure 4C). Fig-
ure 4D shows images of fluorescence-labelled THP-1 monocytes
bound to EA.hy926 cells with and without FA exposure at
50 µm.
2.7. Effects of siRNA Exposure on ELOVL5 Gene Expression in
EA.hy926 Cells
Incubation of EA.hy926 cells with ELOVL5 siRNA significantly
decreased relative gene expression of ELOVL5 compared to non-
siRNA treated cells (p < 0.001) (Figure 5A). ELOVL5 relative
gene expression was decreased by ≈90% after ELOVL5 siRNA
exposure across all conditions; control (DMEM alone) (−90%),
GLA-treated cells (50 µm) (−87%), and PLA-treated cells (50 µm)
(−88%). Control siRNA resulted in unaltered relative gene ex-
pression in EA.hy926 cells under all conditions (DMEM, GLA,
and PLA), indicative of ELOVL5 siRNA specificity.
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Figure 4. A,B) Cell surface expression of ICAM-1 (CD54) in EA.hy926 cells and C) adhesion of THP-1 cells to EA.hy926 cells incubated for 48 h with
DMEM containing 0.1% of ethanol (CTL) or fatty acids (GLA or PLA) at 25 or 50 µm, followed by incubation with TNF-𝛼 (1 ng mL−1) for 6 h (data are
expressed as % of control [A, C] and % difference from control [B], n = 3, one-way ANOVA with Tukey’s post hoc test: Fatty acid vs control, **p < 0.01
and ***p < 0.001). Attached THP-1 cells were visualized by fluorescence microscope Nikon Elipse Ti at a magnification of 10× under transmitted light
(control, GLA, or PLA [3 D]).
2.8. Effects of Silencing ELOVL5 on Incorporation of FAs in
EA.hy926 Cells
FA incorporation into EA.hy926 cells was determined by
gas chromatography. FAs were successfully incorporated by
EA.hy926 cells, with the appearance of specific metabolic elon-
gation products depending on FA (as seen previously). GLA
incubation of non-siRNA treated cells (50 µm) led to a significant
increase in DGLA (p < 0.001) (Figure 5B); similarly after PLA
treatment (50 µm) there was a significant increase in ETA (p <
0.001) (Figure 5B). ELOVL5 siRNA treatment of cells signifi-
cantly inhibited elongation of GLA and PLA to DGLA and ETA
(p < 0.0001 and p < 0.001, respectively) (Figure 5B,C). ELOVL5
silencing in GLA-treated cells led to a build-up of GLA in the cells
(Figure 5B); however PLA build up was not seen in PLA-treated
silenced cells (Figure 5C).
2.9. Effects of Silencing ELOVL5 and FA Treatment on
Inflammatory Mediators Produced by EA.hy926 Cells
GLA and PLA both significantly decreased the secretion of
sICAM-1 compared to stimulated control cells (p < 0.001) (Fig-
ure 5D). This reduction was not seen in ELOVL5 siRNA silenced
cells: incubation of these cells with GLA or PLA led to no changes
in levels of sICAM-1. GLA treatment also led to the significant
decrease of RANTES (p < 0.05) by EA.hy926 cells compared
to stimulated control cells (Figure 5H). This effect of GLA
treatment was not seen in ELOVL5 siRNA treated cells. MCP-1
production was decreased after treatment with both FAs (Fig-
ure 5E), with a greater reduction observed after GLA treatment
compared to PLA (p < 0.001 and p < 0.05, respectively). ELOVL5
silencing prevented the effects of PLA on MCP-1. GLA incuba-
tion in ELOVL5 silenced cells still led to the same significant
decrease in MCP-1 as seen in unsilenced cells (p < 0.001).
Neither IL-6 nor IL-8 production by EA.hy926 cells was affected
by GLA or PLA with or without ELOVL5 siRNA treatment.
2.10. Results of MTT Assay: Effects of DGLA and ETA on
EA.hy926 Cell Viability
Cell mitochondrial activity was measured using the MTT assay
and viability was calculated as a % of control (cells in DMEM
plus supplements). Figure 6A,B shows viability of cells cultured
with DGLA and ETA at 5, 10, 25, and 50 µm. There was a signif-
icant reduction in viability of cells cultured with DGLA and ETA
at 25 µm (p < 0.0001) and 50 µm (p < 0.0001), compared to stim-
ulated control cells (<60%, <70%, <25% viability, respectively).
Based on these results, a maximum concentration of 10 µm for
each of these FAs was chosen for further experiments.
2.11. DGLA and ETA Incorporation into EA.hy926 Cells
Both DGLA and ETA were incorporated into EA.hy926 cells in a
concentration-dependent manner at 5 and 10 µm (Figure 6C,D).
DGLA treatment at 5 and 10 µm led to a significant increase
in DGLA (p < 0.05, p < 0.001, respectively) in EA.hy926 cells
(Figure 6C). Similarly, ETA treatment at 5 and 10 µm led to a
significant increase in ETA (p < 0.05, p < 0.001, respectively)
(Figure 6D).
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Figure 5. A) Expression of ELOVL5 gene in EA.hy926 cells treated with siRNA and incubated for 48 h with DMEM containing 0.1% of ethanol (CTL)
or fatty acids (GLA or PLA) at 50 µm, followed by incubation with TNF-𝛼 (1 ng mL−1) for 24 h (n = 3, one-way ANOVA with Tukey’s post hoc test:
ELOVL5 siRNA vs control, ***p < 0.001). B,C) Incorporation of fatty acids (GLA and PLA) and appearance of elongation products (DGLA and ETA) after
incubation of EA.hy926 cells for 48 h with DMEM containing 0.1% of ethanol (control) or fatty acids (GLA [B] and PLA [C]) at 50 µm with or without
ELOVL5 siRNA (n= 3, two-way ANOVA with Dunnett’s post hoc test: Fatty acid vs control, *p< 0.05, **p< 0.01, ***p< 0.001, and ****p< 0.0001; Fatty
acid vs Fatty acid (GLA or PLA) + ELOVL5 siRNA, $$$$p < 0.001). Concentrations (pg mL−1) of D) ICAM-1, E) MCP-1, F) IL-6, G) IL-8, and H) RANTES
in the medium of EA.hy926 cells incubated for 48 h with DMEM containing 0.1% of ethanol (CTL) or fatty acids (DGLA or ETA) at 50 µm, followed by
incubation with TNF-𝛼 (1 ng mL−1) for 24 h with or without ELOVL5 siRNA (n = 3, two-way ANOVA with Tukey’s post hoc test: Fatty acid vs control,
*p < 0.05 and **p < 0.01).
2.12. Effects of DGLA and ETA on Inflammatory Mediators
Produced by EA.hy926 Cells
Both FAs led to significant decreases in sICAM-1, MCP-1, IL-6,
and RANTES at both 5 and 10 µm (Figure 7A–E). DGLA treat-
ment at 5 and 10 µm lead to significant reduction in secretion
of sICAM-1 (p < 0.0001, p < 0.001, respectively). Production of
bothMCP-1 and RANTES by EA.hy926 cells was significantly de-
creased after exposure to DGLA at both concentrations used (p <
0.0001). DGLA treatment also led to a significant decrease in IL-6
secretion at 5 and 10 µm (p < 0.01) compared to stimulated con-
trol cells.
Similarly, ETA exposure led to significant decreases in sICAM-
1 at 5 µm (p < 0.01) and 10 µm (p < 0.001). MCP-1 and IL-6
production were also decreased by ETA exposure at 5 µm (p <
0.01, p < 0.0001, respectively) and 10 µm (p < 0.0001, p < 0.01).
RANTES secretion was significantly reduced by ETA at both
concentrations (p < 0.0001).
Neither DGLA nor ETA had any effect on production of IL-8
by EA.hy926 cells.
2.13. Effects of DGLA and ETA on NF𝜿Bp65 Protein Expression
in EA.hy926 Cells
Pre-treatment with either DGLA or ETA (10 µm) had a tendency
to decrease the ratio of pNF𝜅Bp65/NF𝜅Bp65, with ETA having
greater potency reaching near significance (p = 0.06) (Figure 7F).
2.14. Effects of DGLA and ETA on Expression of ICAM-1 on
EA.hy926 Cells
Neither DGLA nor ETA treatment at either concentration (5 or
10 µm) had any effect on the level of ICAM-1 expression (MFI)
(Figure 8A) or the% of cells expressing ICAM-1 (Figure 8B) com-
pared to stimulated control cells.
2.15. Effects of DGLA and ETA on THP-1 Adhesion to EA.hy926
Cells
Figure 8D shows images of fluorescence-labelled THP-1 mono-
cytes bound to EA.hy926 cells with and without FA exposure at
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Figure 6. A,B) Viability of EA.hy926 cells after incubation for 48 h with DMEM containing 0.1% of ethanol (control; CTL) or fatty acids (DGLA [A] and
ETA [B]) at 5, 10, 25, or 50 µm followed by incubation with or without TNF-𝛼 (1 ng mL−1) for 24 h (n = 3, two-way ANOVA with Tukey’s post hoc test: Fatty
acid vs control, unstimulated [DMEM], ***p < 0.01; ****p < 0.001; Fatty acid vs control, stimulated [TNF-𝛼 1 ng mL−1], $p < 0.05; $$$$p < 0.0001).
C,D) Incorporation and appearance of fatty acids (DGLA and ETA) after incubation of EA.hy926 cells for 48 h with DMEM containing 0.1% of ethanol
(control) or fatty acids (DGLA [C] and ETA [D]) at 5 or 10 µm, (n = 3, one-way ANOVA with Dunnett’s post hoc test: Fatty acid vs control, *p < 0.05,
**p < 0.01, and ***p < 0.001).
10 µm. DGLA and ETA significantly reduced adhesion of THP-1
cells to EA.hy29 cells at both concentrations (5 and 10 µm) (Fig-
ure 8C). Treatment with DGLA at 5 and 10 µm reduced adhesion
of THP-1 cells by ≈25% and ≈40%, respectively (p < 0.05, p <
0.001) compared to stimulated control cells (Figure 8C). Treat-
ment with ETA at both 5 and 10 µm reduced adhesion of THP-1
cells by ≈50% (p < 0.0001) compared to stimulated control cells
(Figure 8C).
3. Discussion
The functionality of plant-derived FAs such as GLA and PLA has
been underexplored; this study examines the potential for these
FAs to serve as sustainable alternative sources to LC n-3 PUFAs
for human health. GLA and PLA may play a role in controlling
inflammatory processes, including EC responses. In the current
study, both GLA and PLA decreased inflammatory responses of
TNF-𝛼 stimulated ECs, with PLA being more potent than GLA.
The observed effects of GLA and PLA appear to be the result of
metabolism to their longer chain derivatives, DGLA from GLA
and ETA from PLA, as demonstrated by silencing of elongase 5
which reduced or abolishedmost of the anti-inflammatory effects
of GLA and PLA. In accordance with this, DGLA and ETA were
both shown to exert potent anti-inflammatory effects in this EC
model.
The study demonstrated various anti-inflammatory effects
of GLA and PLA in EA.hy926 cells exposed to TNF-𝛼. TNF-
𝛼 has been shown to be crucially involved in the pathogene-
sis and progression of atherosclerosis and alters both EC func-
tion and EC-leukocyte interactions through increases in pro-
inflammatory gene expression and cell adhesion molecules.[30,31]
TNF-𝛼 is used frequently as a stimulus in various inflammatory
EC models[24,26,28,32,33] and was therefore deemed an appropriate
stimulus within this model.
The MTT assay was used as a measure of cell viability in this
study. Neither GLA nor PLA at any concentration had an effect
on MTT readings; however DGLA and ETA were both shown
to reduce MTT assay output at higher concentrations (25 and
50 µm). This suggests DGLA and ETA may influence mitochon-
drial activity. Recent findings by Gallagher et al. suggest DGLA
improves macrophage mitochondrial bioenergetic profile by de-
creasing proton leak, increasing non-mitochondrial respiration,
sparing respiratory capacity, and coupling efficiency.[34] As far as
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Figure 7. Concentrations (pg mL−1) of A) ICAM-1, B) MCP-1, C) IL-6, D) IL-8, and E) RANTES in the medium of EA.hy926 cells incubated for 48 h with
DMEM containing 0.1% of ethanol (CTL) or fatty acids (DGLA or ETA) at 5 or 10 µm, followed by incubation with TNF-𝛼 (1 ng mL−1) for 24 h (n = 3,
two-way ANOVA with Tukey’s post hoc test: Fatty acid vs control, **p < 0.01, ***p < 0.001, and ****p < 0.0001). F) Protein expression of pNF𝜅Bp65
and NF𝜅Bp65 in EA.hy926 cells incubated for 48 h with DMEM containing 0.1% of ethanol (control, CTL) or fatty acids (DGLA or ETA) at 10 µm, followed
by incubation with TNF-𝛼 (1 ng mL−1) for 1 h (data are normalized to loading control [GAPDH], n = 3, one-way ANOVA with Tukey’s post hoc test: no
significant differences).
we are aware no one has examined the effects of ETA on mito-
chondrial activity.
GLA and PLA at a concentration of 50 µm were both shown
to decrease the production of chemokines (MCP-1 and RANTES)
and an adhesionmolecule (sICAM-1). These chemical signals are
all involved in the initiation and development of the atheroscle-
rotic plaque.[1–6] Similar to effects observed here, Kim et al. re-
ported reduced MCP-1 production in rat kidney epithelial cells
(NRK-52E) and in mesangial cells after treatment with GLA at
10 and 100 µm.[35] Gallagher et al. also described reduced ICAM-
1 gene expression in stimulated THP-1 cells after treatment with
GLA (100 µm).[34] However, very few studies have reported effects
of GLA on ECs and there are no studies of PLA and ECs. Nei-
ther GLA nor PLA had any effect on IL-6 or IL-8. Erdinest et al.
also reported lack of effect of GLA on IL-6 and IL-8 production by
LPS-stimulated human corneal ECs,[36] whereas Chen et al. de-
scribed reduced IL-6 production in LPS-stimulated murine mi-
croglial BV-2 cells after PLA treatment.[22] Similarly, Chen et al.
also reported lowered IL-6 production after treatment of differen-
tiated THP-1 cells with PLA.[37] These different findings might
indicate different sensitivities of different cell types to GLA and
PLA or they may reflect differences in experimental conditions
(e.g., inflammatory stimulant, fatty acid concentration, incuba-
tion time). However, taken as a whole, the findings of the current
study, along with these earlier studies,[22,34–37] indicate that both
GLA and PLA have the potential to decrease the production of a
range of key inflammatory chemokines and cytokines.
Neither GLA nor PLA had any effects on the surface expres-
sion of ICAM-1 in EA.hy926 cells. Similarly, De Caterina et al.
reported little effect of GLA on VCAM-1 surface expression on
human saphenous vein ECs.[25] Effects of PLA on cell surface ex-
pression of adhesion molecules in ECs have not been previously
described.
Elongase 5 catalyzes the conversion of GLA to DGLA and
of PLA to ETA; elongase 5 is encoded by ELOVL5. ELOVL5
silencing led to the significant reduction in elongation products
after incubation with GLA or PLA. Incubation with GLA led to
a small increase of GLA in silenced cells, however this was not
significant. PLA did not appear to accumulate in PLA-incubated
silenced cells; this may indicate that these cells are resistant to ac-
cumulating too much PLA, possibly due to its unusual structure.
ELOVL5 silencing led to the full reversal of the effects ob-
served after treatment with PLA: production of sICAM-1, MCP-1,
and RANTES by siRNA treated cells stimulated with TNF-𝛼 was
similar to that seen for control cells (i.e., ECs stimulated with
TNF-𝛼 but without prior exposure to a fatty acid). This suggests
that the anti-inflammatory effects seen with PLA treatment are
due to a metabolic product beyond elongase 5, perhaps ETA.
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Figure 8. A,B) Cell surface expression of ICAM-1 (CD54) in EA.hy926 cells and C) adhesion of THP-1 cells to EA.hy926 cells incubated for 48 h with
DMEM containing 0.1% of ethanol (CTL) or fatty acids (DGLA or ETA) at 25 or 50 µm, followed by incubation with TNF-𝛼 (1 ng mL−1) for 6 h, (data
are expressed as % of control [A, C] and % difference from control [B], n = 3, one-way ANOVA with Tukey’s post hoc test: Fatty acid vs control, **p <
0.01 and ***p < 0.001). Attached THP-1 cells were visualized by fluorescence microscope Nikon Elipse Ti at a magnitude of 10× under transmitted light
(control, DGLA or ETA [7 D]).
However, effects seen with GLA were only partially reversed by
ELOVL5 silencing. Decreases seen with GLA in both sICAM-1
and RANTES production were reversed in siRNA treated cells,
whereas MCP-1 production remained significantly lower in
siRNA-treated cells compared to control cells. This may indicate
a direct role for GLA in the inhibition of MCP-1 production in
ECs. However, just as for PLA, the observations suggest that at
least some of the anti-inflammatory effects seen with GLA treat-
ment are due to a metabolic product beyond elongase 5, perhaps
DGLA. DGLA was also shown to reduce production of MCP-1
in this model. Others have described a reduction in MCP-1 gene
expression in stimulated THP-1 cells after treatment with both
GLA (100 µm) and DGLA (50 µm).[34]
Both DGLA and ETA exhibited potent anti-inflammatory
effects within this EC model, leading to reduced production of
MCP-1 as well as sICAM-1, RANTES, and IL-6. Effects of DGLA
and ETA on these outcomes in ECs have not been previously
described. Gallagher et al. describe reduced ICAM-1 gene ex-
pression in stimulated THP-1 cells after incubation with DGLA
(50 µm).[34] In another study Chen et al described reduced IL-6
production in LPS-stimulated BVmicroglial cells after treatment
with ETA (50 µm).[22] Similarly Huang et al. indicated that
pre-treatment with ETA led to a reduction in IL-6 production by
RAW264.7 macrophages, but the data was not shown.[38]
Both GLA and PLA led to decreased adhesion of THP-1 cells
to EA.hy926 cells. No others have explored the effects of either
of these FAs on adhesion of monocytes to EC monolayers.
However, one study describes reduced migration of THP-1
monocytes after incubation with GLA (50 µm).[34] DGLA and
ETA were shown to also reduce adhesion of THP-1 cells to
EA.hy926 cells, at lower concentrations and with greater potency
than seen with GLA and PLA. Others have described reduced
migration of human aortic smooth muscle cells pre-treated with
DGLA at 50 µm,[34] but again there are no previous reported
studies of effects of ETA on these cell properties.
Together the results from this study clearly suggest that the
metabolism of GLA and PLA plays a critical role in the bioac-
tivity of these FAs, with most of their effects likely due to the
elongation products DGLA and ETA. GLA and PLA were shown
to be incorporated into cells in a concentration-dependent man-
ner with the appearance of elongation products, DGLA from
GLA and ETA from PLA. DGLA can be further metabolized via
delta-5 desaturase to AA. However, incubation with GLA did
not lead to increased AA in EA.hy926 cells. Similar observa-
tions have been made in human studies where increased GLA
intake has led to increased DGLA in PBMCs and neutrophils
with no effect on AA.[39–43] Previous studies have therefore at-
tributed the anti-inflammatory actions of GLA to its conver-
sion to DGLA. DGLA can be metabolized by both cyclooxyge-
nase (COX) 1 and COX 2 to 1 series prostaglandins and by 15-
lipoxygenase into 15-(S)-hydroxy-8,11,13-eicosatrienoic acid (15-
HETrE).[44,45] These metabolites of DGLA have been shown to
suppress inflammation.[21,46,47] DGLA treatment (100 µm) was
shown to increase levels of prostaglandin (PG) E1 produced
by THP-1-derived macrophages.[34] Others have described treat-
ment with PGE1 to reduce several inflammatory processes in
ECs, including lowered ICAM-1 and VCAM-1 as well as reduced
monocyte adhesion to EC monolayers; these effects were shown
to be through suppression of TNF-induced NF𝜅B activation.[48]
Therefore, anti-inflammatory actions of GLA and furthermore
DGLA in this model are possibly through production of PGE1.
Very few studies have described effects of ETA on inflamma-
tory processes, and none have examined effects with ECs. It is
likely that metabolites of ETA may also suppress inflammation
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in a similar way to those produced from DGLA. Huang et al.
described reduced pro-inflammatory PGE2 after treatment of
RAW264.7 cells with ETA.[38]
NF𝜅B drives the expression of pro-inflammatory genes.[49,50]
EPA and DHA have been shown to inhibit the activity of NF𝜅B,
leading to decreases in expression of genes encoding various
inflammatory chemokines, cytokines, adhesion molecules, and
enzymes.[13,51] These effects are linked to reduced leukocyte-
EC adhesive interactions and reduced leukocytic infiltration
into tissues.[13,51] These effects might be important in decreas-
ing initiation and development of atherosclerotic plaques.[52]
Observations made in the current study suggest that the de-
creased production of inflammatory mediators by ECs and the
decreased THP-1 cell adhesion seen with GLA and PLA (and
also with DGLA and ETA) may be due to reduced activation of
NF𝜅B. Incubation of EA.hy926 cells with PLA and ETA lead
to decreased phosphorylation (activation) of NF𝜅B; GLA and
DGLA also appeared to reduce the activation, although not to
the same extent. No previous studies have described effects of
GLA, DGLA, PLA, nor ETA on NF𝜅B activation in ECs. Also,
few studies have examined effects of these FAs on NF𝜅B in
other cell types. Cao et al. reported significantly reduced NF𝜅B
activity after treatment with GLA at 100 µm in LPS-stimulated
primary goat mammary gland epithelial cells.[53] One other
study described decreased NF𝜅B activity (nuclear translocation)
in LPS-stimulated RAW264.7 macrophages after treatment with
both PLA and ETA at 50 and 100 µm.[38]
The need for sustainable, non-fish alternatives to marine-
derived FAs requires exploration into plant-derived FAs.GLA and
PLA, which are both plant derived, have anti-inflammatory ac-
tions within this ECmodel, reducing production of cytokines and
chemokines and THP-1 monocyte adhesion, likely through inhi-
bition of the NF𝜅B pathway. The effects of GLA and PLA did not
occur in ELOVL5 silenced cells, suggesting that metabolites of
GLA and PLA are mainly responsible for their effects. In agree-
ment with this, greater anti-inflammatory potency was observed
with DGLA and ETA than with GLA and PLA. GLA and PLA
may provide a sustainable source of bioactive FAs for health ben-
efits, especially in the context of endothelial inflammation and
atherosclerosis.
Strengths of the current study include confirmation of the in-
corporation of the FAs used into the cells; evaluation of the effect
of different concentrations of FAs for several of the experiments;
integrated examination of the effects of the FAs on aspects of cell
signaling, protein expression, secreted proteins, and binding of
ECs tomonocytes; and the novel examination of the effects of un-
or underexplored plant-derived FAs. One limitation of the study
is that it examined the effects of only a single period of exposure
of the FAs to the ECs (48 h). Furthermore, the study used only a
single inflammatory stimulus, TNF-𝛼, and it would be interest-
ing to examine other stimuli such as lipopolysaccharide or IL-6.
In order to confirm efficacy of siRNA treatment it would be ben-
eficial to examine elongase 5 protein concentrations alongside
ELOVL5 gene expression in ELOVL5 silenced cells; however the
EC fatty acid concentration changes reported are consistent with
reduced elongase 5 enzyme activity which would result from less
protein being present. Finally, the EA.hy926 EC line was used;
although this cell line maintains many of the innate properties
of primary ECs,[54] it may have some differences in properties or
responses. We have previously verified that effects of EPA and
DHA seen with EA.hy926 cells[28] are similar to those reported
for other types of EC.[23–26,32,55–57]
It is important to also consider the concentrations of the FAs
used in the current experiments. The concentrations of GLA,
PLA, and ETA used are likely to exceed those present in hu-
man plasma; the concentrations of these FAs are not routinely
reported in human plasma and are considered to be very low.
Studies supplementing humans with GLA report that GLA it-
self does not accumulate in plasma lipids[39,58] or in white blood
cells.[39–43,59] In contrast, DGLA is readily detectable in human
plasma and in white blood cells and accumulates when GLA is
given.[39–43,58,59] Miles et al.[60] reported DGLA as a weight per-
centage of fatty acids in plasma triglycerdes, phospholipids, and
cholesteryl esters prior to and after 12 weeks of daily supplemen-
tation with 2 g GLA. Weight percentages changed from 0.36 to
0.48, 3 to 4.8, and 0.74 to 1.20, respectively. Hodson et al.[61]
quote a mol% contribution of DGLA to total plasma fatty acids
of 1.1%. Using typical fasting plasma concentrations of triglyc-
erides, phospholipids, cholesteryl esters, and non-esterified fatty
acids of 1, 3, 4, and 0.6 mm (equivalent to 3, 6, 4, and 0.6 mm of
fatty acids), 1.1 mol% equates to a total DGLA concentration in
plasma of 150 µm. This concentration of DGLA might as much
as double after supplementation with GLA. Hence, the concen-
trations of DGLA used in the current study are lower than the
total plasma concentration of DGLA that is typically seen. How-
ever, most DGLA in plasma is esterified into triglycerides, phos-
pholipids, and cholesteryl esters but in the current experiments
free, non-esterified DGLA was used. Hodson et al.[61] state that
DGLA typically contributes 0.1 mol% to plasma non-esterified
fatty acids; this would equate to a concentration of <1 µm well
below the concentrations used here.
It is concluded that the plant-derived FAs GLA and PLA ex-
ert anti-inflammatory effects, mainly through conversion to their
elongated derivatives DGLA and ETA. The context of the cur-
rent research is the initiation and progression of atheroscle-
rotic plaques that predispose to coronary heart disease and other
CVDs. Effects of GLA and PLA should be further explored in
other cell systems, in relevant animal models and in humans.
4. Experimental Section
Endothelial Cell Culture: EA.hy926 cells (ATCC, LGC standards, Mid-
dlesex, UK) were cultured in high glucose DMEM supplemented with 10%
fetal bovine serum, 1% L-glutamine-penicillin-streptomycin solution, and
1% HAT (100 µm hypoxanthine, 0.4 µm aminopterin, and 16 µm thymi-
dine); medium and supplements were purchased from Sigma-Aldrich
(Gillingham, UK). Cultures were maintained at 37 °C in humidified 95%
air and 5% CO2.
Fatty Acid Treatment of Endothelial Cells: GLA (Sigma-Aldrich), PLA,
DGLA, and ETA (Larodan, Sweden) were prepared as 50, 25, 10, or 5 mm
stocks in 100% ethanol. Experimental FA concentrations were achieved by
diluting stock solutions in complete medium to 5, 10, 25, and 50 µm in a
final concentration of 0.1% ethanol.
Assessment of Cell Viability: Cell viability was assessed using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay which
measures cellular mitochondrial activity. EA.hy926 cells were incubated in
the presence of FAs at concentrations of 10, 25, or 50 µm for 48 h and
further exposed to complete medium with or without TNF-𝛼 (1 ng mL−1
final concentration) for 24 h. After incubation, supernatant was removed
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and replaced with DMEM containing 0.05 mg mL−1 MTT (Sigma-Aldrich)
(100 µL per well) and samples incubated at 37 °C for 4 h. Supernatants
were removed (75 µL) and 75 µL of DMSO added (Sigma-Aldrich). Sam-
ples were then incubated for at 37 °C for 30 min before reading the ab-
sorbance at 540 nm on a plate reader. The effects of FAs and TNF-𝛼 on
cell viability were normalized to control (0.1% ethanol, i.e., no FA or TNF-
𝛼) cultures (100%).
Determination of Fatty Acid Composition of Endothelial Cells by Gas Chro-
matography: The FA composition of EA.hy926 cells after culture with
various FAs was determined using gas chromatography. Total lipid was
extracted from EA.hy926 cells using chloroform/methanol as described
elsewhere.[62] Lipid extracts were dried under nitrogen. FAs were cleaved
from these isolated lipids and simultaneously methylated by heating with
methanol and sulfuric acid at 50 °C for 2 h. The FA methyl esters were
extracted into hexane and then separated and analyzed by gas chromatog-
raphy using conditions described by Fisk et al.[62] FAs were identified by
comparison of retention times with those of authentic standards and are
expressed as µg per 106 cells.
Identification of Unknown Fatty Acid by Gas Chromatography–Mass Spec-
trometry: The identification of an unknown FA in EA.hy926 cells after
culture with PLA was made using gas chromatography/mass spectrom-
etry. Preparation of FA methyl esters from total lipid extracts of EA.hy926
cells was performed as described in the previous section. FA methyl es-
ters were separated by gas chromatography using conditions similar to
those described by Fisk et al.[62] The gas chromatograph was fitted with
a SGE BPX-70 30 m × 0.2 mm × 0.25 µm capillary column, and helium
was used as carrier gas at a total flow rate of 50 mL min−1 with 1.58 mL
min−1 through the column. The injector was kept at 250 °C using the split-
less injection mode, and 1 µL injections were made. The temperature was
kept constant at 115 °C for 2 min, with a linear increase at 10 °C min−1
to 200 °C thereafter; this temperature was held for 18 min after which the
column was held at 245 °C for a final 5 min. Total run time was 35 min.
The unknown FA methyl ester was subsequently identified by mass spec-
trometry detection using a Shimadzu QP2010nc system equipped with an
AOC5000 autosampler. The quadrupole detector was operated in full scan
semi-electron impact (SEI) electrospray ionizationmode covering them/z
range of 40–500. Detector voltage was 0.95 kV, and the temperature of the
ion source and interface were set to 230 and 250 °C, respectively. FAs were
identified according to their mass-to-charge ratio (m/z) and by the com-
parison of ion fragments to those of authentic standards.[29]
Measurement of Inflammatory Mediator Concentrations: The concen-
trations of inflammatory mediators (interleukin (IL)-6, IL-8, intercellular
adhesion molecule (ICAM)-1, regulated on activation normal T cell ex-
pressed and secreted (RANTES) and monocyte chemoattractant protein
(MCP)-1) secreted by EA.hy926 cells were determined simultaneously us-
ing Human magnetic Luminex Screening Assay kits (R&D Systems, Min-
neapolis,MN). Assays were conducted in accordance with the instructions
from the manufacturer. Plates were analyzed on a calibrated Bio-Plex 200
analyzer using Bio-Plex software (version 6.1, Bio-Rad Laboratories Inc.,
Berkeley, CA). Lower limits of detection were: IL-6 (1.7 pg mL−1), IL-8
(1.8 pg mL−1), MCP-1 (9.9 pg mL−1), RANTES (1.8 pg mL−1), and ICAM-
1 (87.9 pg mL−1).
Assessment of Cell Surface ICAM-1 Expression: Surface expression of
ICAM-1 (CD54) on EA.hy926 cells was determined using flow cytometry.
Cells were exposed to FAs at 25 and 50 µm for 48 h followed by stimula-
tion with TNF-𝛼 (1 ng mL−1) for 6 h. Following this, cells were detached,
centrifuged, and stained with phycoerythrin (PE)-conjugated monoclonal
anti-human CD54 (BD Biosciences, San Jose, CA) diluted in staining so-
lution (PBS, 2% BSA) for 30 min. Mouse IgG1 (PE) isotype was used as
a negative control. After staining, cells were analyzed by flow cytometry
using an FACSCalibur flow cytometer (BD Biosciences). A total of 10 000
events were collected. Percentage positive cells and median fluorescence
intensity (MFI) were determined.
Protein Extraction and Western Blotting: The expression of NF𝜅Bp65,
pNF𝜅Bp65, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
was assessed by Western blotting. Cells were exposed to FAs at 50 µm
for 48 h followed by stimulation with TNF-𝛼 (1 ng mL−1) for 1 h. Pro-
tein was extracted from cells using radioimmunoprecipitation assay buffer.
Protein was quantified using the BCA assay (Pierce, ThermoFisher Scien-
tific) following the manufacturer’s instructions. Then, samples were di-
luted and a total of 30 µg of protein loaded onto pre-cast 10% SDS gels
(Obtiblot, Abcam, Cambridge, UK) alongside a Prism Ultra Protein Lad-
der (10–245 kDa). Gels were run for 1.5–2 h and proteins transferred onto
a nitrocellulose membrane which was probed with antibodies (Abcam;
NF𝜅Bp65 (ab32536), phosphorylated NF𝜅Bp65 (ab76302), and GAPDH
(ab181602). Western blots were quantified using ImageJ software and rel-
ative quantification values were presented as the ratio of each protein band
relative to the loading control (GAPDH).
Monocyte Adhesion to Endothelial Cells: Adhesion of monocytic THP-1
cells to EA.hy926 cells was determined using the Vybrant Cell Adhesion As-
say Kit (ThermoFisher Scientific). EA.hy926 cells were exposed to FAs at 5,
10, 25, or 50 µm for 48 h followed by stimulation with TNF-𝛼 (1 ng mL−1)
for 6 h. After stimulation, calcein-labeled THP-1 cells were incubated with
EA.hy926 cells for 1 h at 37 °C. Non-adherent THP-1 cells were removed by
gentle washing, 100 µL PBS added to each well and co-cultures read on the
Glomax Discover System (Promega). THP-1monocyte adhesion wasmea-
sured as a percentage of control (non-stimulated DMEM treated cells).
Images of fluorescence-labeled THP-1monocytes bound to EA.hy926 cells
were taken with a Nikon Elipse Ti using NIS elements software (version
4.30).
Elongase 5 Gene Silencing: Silencing of the elongase 5 gene (ELOVL5)
in EA.hy926 cells was achieved by siRNA-mediated inhibition of ELOVL5
using Santa Cruz reagents and protocol (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA). EA.hy926 cells were incubated in antibiotic-free culture
medium for 24 h followed by 6 h incubation with siRNA transfection
reagent mixture (1 mL), containing ELOVL5 siRNA or control siRNA and
siRNA transfection reagent (all Santa Cruz Biotechnology Inc.). Medium
was then removed and replaced with complete culture medium for 24 h.
Finally, EA.hy926 cells were incubated in the presence of FAs (GLA or PLA)
at a concentration of 50 µm for 48 h; cells were then either removed for
FA composition analysis, or further exposed to complete medium with or
without TNF-𝛼 (1 ng mL−1 final concentration) for 24 h, for supernatant
inflammatory mediator analysis.
RNA Isolation, cDNA Synthesis, and Real-Time PCR: Changes in rel-
ative gene expression were analyzed by RT-PCR. Cells were exposed to
siRNA silencing protocol followed by FA treatment for 48 h and finally stim-
ulation with TNF-𝛼 (1 ngmL−1) for 24 h. TaqmanGene Expression Primers
(ThermoFisher Scientific, Waltham, MA) were used to determine the ef-
fect of silencing ELOVL5 (Hs00765730_m1) in EA.hy926 cells. Total RNA
was isolated using the ReliaPrep RNA cell Miniprep System (Promega,
Southampton, UK). RNA quantity and quality were analyzed byNanoDrop.
Analysis of RNA using Agilent Bioanalyzer (RNA Total Eukaryote 2100
Nano) was performed to determine RNA RIN scores. cDNA was synthe-
sized from total RNA using GoScript Reverse Transcriptase (Promega).
Housekeeping reference genes were determined using a geNorm Kit
(Primerdesign, Camberley, UK). Quantification of relative gene expression
was analyzed using B2M, (Hs00187842_m1), GAPDH (Hs02786624_g1),
and RPL13A (Hs04194366_g1) as housekeeping genes.
Statistics/Data Analysis: Data were presented as mean ± SEM and
were analyzed by two-way analysis of variance (two-way ANOVA) or one-
way analysis of variance (one-way ANOVA) followed by post-hoc tests of
pairwise differences. Analyses were performed using GraphPad Prism 6.0.
Differences were considered significant when p < 0.05.
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